Table 1.
Patient group | Control group | t | χ2 | ||
---|---|---|---|---|---|
Number of subjects | 58 | 54 | |||
Number of eyes | 62 | 54 | |||
Number of males | 25 | 25 | 0.138 | ||
Number of females | 33 | 29 | |||
Number of left eyes | 32 | 26 | 0.089 | ||
Number of right eyes | 30 | 28 | |||
Intraocular pressure (mmHg) | 12±0.57 | 14±0.32 | 0.386 | ||
Age (years) | 56.68±7.14 | 57.23±6.22 | −0.657 | ||
Number of days from onset to admission | 4.36±3.22 | ||||
Vision (BVCA) ≤0.3 | 18 eyes (29.03%) | 0.8–1.0 | |||
BVCA, 0.4–0.6 | 30 eyes (48.39%) | ||||
BVCA, 0.7–1.0 | 14 eyes (22.58%) (four eyes with BCVA=1.0) | ||||
logMAR BCVA | 0.68±0.79 | 0.07±0.06 | |||
Temporal altitudinal field defect connected with optic disc | 16 eyes | ||||
Inferior altitudinal field defect connected to the optic disc | 26 eyes | ||||
Superior altitudinal field defect connected to optic disc | 8 eyes | ||||
Nasal defects | 6 eyes | ||||
Tubular vision, visual island, or diffuse visual field defects | 6 eyes |